Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Sells $1,273,584.95 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Iqbal J. Hussain sold 77,705 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $16.39, for a total value of $1,273,584.95. Following the transaction, the general counsel now directly owns 125,785 shares of the company’s stock, valued at $2,061,616.15. This trade represents a 38.19 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Centessa Pharmaceuticals Trading Up 5.1 %

CNTA stock opened at $17.60 on Wednesday. The stock has a market cap of $2.32 billion, a price-to-earnings ratio of -11.50 and a beta of 1.52. The company has a fifty day moving average price of $16.56 and a two-hundred day moving average price of $13.46. Centessa Pharmaceuticals plc has a one year low of $6.65 and a one year high of $18.97. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.05. Equities analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Nantahala Capital Management LLC acquired a new stake in Centessa Pharmaceuticals during the 2nd quarter worth approximately $4,064,000. Driehaus Capital Management LLC increased its position in Centessa Pharmaceuticals by 89.5% during the 2nd quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock worth $18,891,000 after buying an additional 987,997 shares during the period. Ally Bridge Group NY LLC bought a new position in Centessa Pharmaceuticals during the 3rd quarter worth $4,951,000. GSA Capital Partners LLP lifted its holdings in shares of Centessa Pharmaceuticals by 66.1% during the third quarter. GSA Capital Partners LLP now owns 93,658 shares of the company’s stock worth $1,498,000 after buying an additional 37,275 shares in the last quarter. Finally, First Light Asset Management LLC boosted its position in shares of Centessa Pharmaceuticals by 59.2% in the second quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company’s stock valued at $43,168,000 after acquiring an additional 1,778,515 shares during the period. Institutional investors own 82.01% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Jefferies Financial Group upped their price objective on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. B. Riley initiated coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, September 19th. They set a “buy” rating and a $33.00 price target on the stock. Morgan Stanley upgraded shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $11.00 to $26.00 in a research note on Thursday, September 19th. BMO Capital Markets boosted their price objective on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a research note on Monday, September 16th. Finally, Guggenheim upped their target price on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 15th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.